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Summary 
Mast cells (MC) play a central role in extrinsic allergic reactions such as asthma and may participate 
in other inflammatory and fibrotic processes. However, with the exception of immunoglobulin 
E (IgE) receptor-dependent stimulation, no secretagogues  of human lung MC have yet been 
described.  It is also unclear whether mediator release can be regulated by certain cytokines as 
demonstrated previously in basophils and other human inflammatory effector calls. Here, we 
show that the c-kit ligand (KL), a recently identified stem call growth factor, at concentrations 
10-100 times lower than that required to promote cell proliferation, enhances the rdease of histamine 
and leukotriene C4 in response to IgE receptor crosslinking of human lung MC. KL does not 
induce mediator release per se, but increases the sensitivity of MC to anti-IgE receptor stimulation 
and also enhances mediator release to maximally effective concentrations of anti-IgE receptor 
antibody. By contrast, a large number of cytokines examined, including the mast cell growth 
factors/agonists in rodents, interleukin 3 (IL-3), II.,4, II.-9, and nerve growth factor, were ineffective 
in this respect.  These findings suggest a unique role of KL in regulating effector functions of 
human mucosal MC. 
T 
he role of human mast cells (MC) 1 in mediating allergic 
reactions is well known (1-4). The occurrence of MC 
mediators such as histamine and arachidonic acid metabolites 
after in vivo exposure of asthmatic individuals to inhalative 
allergens implicates MC as major effector cells in allergic lung 
disease (1). Furthermore, there is increasing evidence that MC 
are involved in delayed-type hypersensitivity diseases and other 
pathophysiologic processes such as wound healing, fibrosis, 
and neuroimmunologic disorders (4-6). MC are found pre- 
dominantly in the skin, lung, heart, and intestine; they rep- 
resent the only tissue cell type containing histamine and 
bearing high-affinity IgE receptors (1-4). In rodents, two sub- 
populations of MC have been identified: connective tissue- 
type MC, found in the skin and the peritoneal cavity, and 
mucosal MC, found predominantly in the respiratory tract 
and gastrointestinal mucosa (3, 4). In humans, the existence 
of a similar heterogeneity of MC is suggested by histochem- 
ical and functional studies (4). Whereas MC from human 
skin respond to various stimuli such as anti-IgE, the anaphy- 
latoxins C3a and C5a, and the neuropeptide substance P (7, 
8), IgE receptor crosslinking represents the only known way 
to induce mediator release in mucosal-type human lung MC. 
1 Abbreviations used in this paper: anti-IgER Ab, mAb against high affinity 
IgE  receptor; FGF, fibroblast growth  factor; GM-CSF, granulocyte/ 
macrophage CSF; IGF, insulin-like growth factor; KL, c-kit ligand; LIF, 
leukemia inhibitory factor; LTC4, leukotriene C4; MC, mast cell; NGF, 
nerve growth factor; rhuKL, recombinant human ILL. 
Several studies have shown that the effector function of 
inflammatory effector  leukocytes such as neutrophils, eo- 
sinophils, and basophils is regulated by distinct sets of cytokines 
(9-15).  For example, basophil mediator release in response 
to IgE receptor crosslinking and to diverse other IgE-indepen- 
dent agonists is strongly modulated by the hematopoietic 
growth factors IL,3, IL-5, granulocyte/macrophage CSF (GM- 
CSF), and nerve growth factor (NGF) (13-15; Bischoff, S. C., 
and C. A. Dahinden, manuscript submitted for publication). 
In the rat, peritoneal MC release histamine in response to 
NGF (16). By contrast, it is largely unknown whether cyto- 
kines or growth factors affect MC mediator release in humans. 
Recently, a novel hematopoietic growth factor named stem 
cell factor, mast cell growth factor, or c-kit ligand (KL) has 
been identified in rodents. In the rodent system, KL is in- 
volved in hematopoiesis, gametogenesis, and development of 
MC and melanocytes (17). By use of KL cDNA as a probe, 
the human homologue was cloned and the soluble form of 
recombinant human KL protein (rhuKL) was expressed and 
purified (18). However, with the exception of a stimulator), 
activity on colony formation in bone marrow cultures in syn- 
ergy with IL-3, G-CSF, GM-CSF, and erythropoietin (18-20), 
the biological effects of KL in the human system are poorly 
defined. 
In this study we show that low concentrations of rhuKL 
strongly enhance IgE-dependent mediator release by human 
lung MC. This observation suggests that KL has an impor- 
tant role in MC-associated  lung diseases, such as asthma. 
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Reagents.  Commercial reagents were obtained from the fol- 
lowing sources: Hepes, Calbiochem-Behring Corp. (I.a Jolla, CA); 
EDTA, Fluka AG (Buchs, Switzerland); Percoll and gelatin, Phar- 
macia Fine Chemicals (Uppsala,  Sweden);  DNase I, pronase,  col- 
lagenase D, elastase, and fatty acid-free BSA, Boehringer Mann- 
heim Inc. (Mannheim, FRG); chymopapain, Sigma Chemical Co. 
(St.  Louis,  MO).  All other reagents were of the highest purity 
available. 
Buffers.  Tyrode buffer contains 137 mM NaCI, 2.7 mM KC1, 
0.36 mM NazHPO4, and 5.55 mM glucose.  TE buffer is Tyrode 
buffer containing 2 mM EDTA. TGMD buffer is Tyrode buffer 
supplemented with gelatin (1 mg/ml),  1.23 mM MgC12, and 15 
/~g/ml DNAse.  Hepes buffer contains 20 mM Hepes,  125 mM 
NaC1, 5 mM KC1, and 0.5 mM glucose. HA buffer is Hepes buffer 
plus BSA (0.25 mg/ml). HACM buffer is HA buffer supplemented 
with 1 mM CaClz  and 1 mM MgC12. 
Cell Pre~ration.  Human lung MC were isolated by the four- 
step enzymatic tissue  dispersion  method described by Schulman 
et al. (21) with some modifications. Macroscopically normal human 
lung tissue (10-40 g) was obtained from pneumoectomy or lobec- 
tomy specimens removed from patients with lung cancer. Immedi- 
ately after resection the tissue  was placed in TE buffer at 4~ 
Within 1-2 h, lung tissue was dissected free of major bronchi and 
blood vessels, cut into fragments of 0.2-1 g, washed twice in TE 
buffer, and incubated in TE buffer containing pronase (3 mg/ml) 
and chymopapain (0.75 mg/ml) at room temperature. During this 
first digestion step, the tissue was chopped finely with scissors. After 
20 rain the lung fragments were separated from freed ceils by filtra- 
tion through a polyamid Nybolt filter (pore size, 300 #m; Swiss 
Silk Bolting Cloth Manufacturing Co. Ltd., Zfirich, Switzerland), 
before repeating the first digestion step under identical conditions. 
The lung fragments were then washed in TGMD buffer and in- 
cubated twice for 20 rain at 30~  in TGMD buffer containing 
collagenase D (1.5 mg/ml) and dastase (0.15 mg/ml). These diges- 
tion steps were also followed by separating freed cells from the lung 
fragments by filtration. The freed cells obtained after digestion steps 
3 and 4 were pooled, washed twice in HA buffer (400 g, 10 min, 
4~  filtered through a Nybolt filter (pore size, 100/~m), and finally 
resuspended in HACM buffer at a cell density of 0.5-2  x  106 
cells/ml. 
Differential counts of cytocentrifuge smears stained with May- 
Griinwald-Giemsa revealed a MC percentage of 4-14% after enzy- 
matic digestion. In some experiments, MC were further purified 
by discontinuous Percoll gradient centrifugation. Percoll gradients 
were hyered in 2-ml aliquots of 1.090, 1.080, 1.070, and 1.062 g/ml 
Percoll solutions,  the latter containing ,'~107 cells. The tubes were 
centrifuged (500g, 40 min, 20~  and cells at each interface were 
collected, washed twice in HA buffer (400 g, 10 min, 4~  and 
resuspended in HACM buffer. MC found at the 1.070/1.080 and 
1.080/1.090 interfaces were free (<1%) of other lung tissue cells, 
whereas the cell fractions at the 1.062/1.070 and <1.062 interfaces 
contained variable proportions of tissue cells and 20% and 3% MC, 
respectively. 
Mediator Release Assay.  The release experiments were performed 
in a  shaking water bath at 37~  as described (13-15).  After a 
warming-up period of 10 min, the cells were preincubated with 
cytokines or in buffer for 20 min or as indicated, followed by the 
addition of the triggering agent. Unless indicated otherwise, the 
release reaction was stopped by placing the tubes in ice-cold water 
40 min after addition of  the second stimulus. Cells were separated 
from supernatants by centrifugation (400 g, 10 rain, 4~  Hista- 
mine and sulfidoleukotrienes (LTC4/D4/E4) were measured in the 
supernatants as described  (13-15; Bischoff, S. C., and C. A. Da- 
hinden, manuscript submitted for publication). Histamine content 
per MC was 2.5  _+ 0.3 pg (mean  _+ SEM from all experiments), 
as determined by measurement of total histamine per milliliter of 
cell suspension  after lysis. Although no basophils  were found in 
dispersed lung cells by microscopy, as a further control of basophil 
contamination, the MC were sequentially exposed to IL-3 and FMLP 
in all the experiments. Under these conditions being optimal for 
basophil mediator release, no mediator released by MC occurred (15). 
CellStirauli.  The soluble forms of  purified recombinant human 
KL (rhuKL; molecular mass of 18.6 kD; 165 amino acids; end se- 
quences: MEGICRNKVT  ...... TKPFMLPPVA, single-letter code) 
and murine KL (rmuKL; molecular mass of 18.4 kD; 165 amino 
acids; end sequences: MKEICGNtrV'T.  ....  .TKPFMLPPVA) were 
kindly provided by Hoffman-La Roche (Basel, Switzerland). In some 
experiments, unpurified COS-superuatants containing recombinant 
murine KL provided by the Genetics Institute (Cambridge, MA) 
was used. Dilutions at 1:200 of the COS-conditioned medium gave 
half-maximal activity as measured by the MO-7 proliferation assay 
(22). KL dilutions were made in Hepes buffer containing BSA (1 
mg/ml). All other cytokines were used in the recombinant human 
form: 11.-1 (15, 23), IL-3 (13-15), Ib5 (15), IL-8 (24) GM-CSF (13, 
15, 25), TNF-cr  (23), and NGF (Bischoff, S. C., and C. A. Da- 
hinden, manuscript submitted for publication); IL-4 and TGF-B 
were provided by Sandoz Ltd. (Basel, Switzerland);  INF-v was from 
Hoffmann-La Roche; IL-9, macrophage CSF (M-CSF), and leukemia 
inhibitory factor (LIF) were gifts from the Genetics Institute; Ib2, 
II_-6, and granulocyte CSF (G-CSF) were purchased from Amgen, 
Inc.  (Thousand Oaks, CA); IIr  was from Bissendorf Biochem- 
icals (Hannover, FKG); fibroblast growth factor (FGF) and insulin- 
like growth factor I (IGF I) were from Boehringer Mannheim. MC 
were triggered for mediator release by the purified mAb 29C6 
directed against a non-IgE-bindiug epitope of the high-affinity IgE 
receptor o~ chain (anti-IgER Ab). This antibody, which binds with 
high affinity (Ka =  3.2 nM) to the IgE receptor, was a generous 
gift from Hoffmann-La Roche (Nutley, NJ). Anti-IgE mAb LE27 
(anti-IgE Ab) was purified as described (25); polyclonal anti-IgE 
serum  was  purchased  from  Serotec,  Inc.  (Oxford,  UK).  The 
complement-derived anaphylatoains C3a and CSa were purified from 
human serum (14, 25).  Platelet-activating factor C18 (PAF) was 
purchased from Novabiochem (l~ufelfingen, Switzerland),  sub- 
stance P from Boehringer Mannheim, and FMLP from Bachem 
AG (Bubendorf, Switzerland). All substances were stored in small 
concentrated aliquots at  -70~  and thawed once before use. 
Data Presentation.  All experiments were performed in duplicate 
and repeated at least three times. Data from multiple experiments 
are presented as mean  +_  SEM. Histamine release is expressed as 
nanograms of histamine/10  s MC, leukotriene release as picograms 
of sulfidoleukotrienes/10  s MC. 
Results 
KL Enhances MC Mediator Release in Response to IgE Receptor 
Stimulation.  Fig.  1 shows the release of histamine and leu- 
kotrienes induced by a maximally effective concentration of 
anti-IgER antibody (Ab) in dispersed human lung MC prein- 
cubated for 20 rain in buffer or with an optimal concentra- 
tion of human KL. The experiments demonstrate that KL 
enhanced IgE receptor-dependent mediator release in all 12 
experiments performed with MC isohted from different lung 
specimen, albeit to a somewhat variable degree (24.5  _+  4.2 
vs.  62.3  _+  6.2  ng  of histamine/10 s  MC;  712  _+  161  vs. 
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Figure  l.  Effect of KL preincubation  on mediator  release by human 
lung MC. Dispersed human lung MC were preincubated in buffer or with 
an optimal concentration  of human KL (10 ng/ml) for 20 min and then 
stimulated with a maximally effective concentration  of anti-IgE  receptor 
mAb 29C6 (a_K, 100 ng/ml) for another 40 rain. Histamine (left) and leu- 
kotriene C4 (n'gh  0  release is shown. Each point represents the mean of 
two determinations  from one experiment;  12 experiments  with different 
MC preparations were performed. Data with and without KL of the same 
MC preparations are connected  by lines. 
2,006  +_  358 pg LTC4/10 s MC; mean  +_ SEM without and 
with KL). KL augmented the release of both preformed and 
newly synthesized mediators to a similar extent (histamine, 
226  +  56%; LTC4, 242  _+  36% enhancement).  KL by it- 
self, even at 10-fold higher concentrations than required for 
maximal  synergistic effects, failed to induce any detectable 
LTC4 generation  and caused minimal  histamine  release in 
only 5 of 12 experiments (0.49  _+  0.25 ng of histamine/10 s 
MC). The potentiation  of mediator release by KL was not 
affected by the presence of contaminating  lung tissue cells, 
since identical results were obtained by unfractionated dis- 
persed lung cells and MC preparations depleted of tissue cells 
by PercoU gradients (not shown). 
Fig. 2 shows the effect of preincubation with KL on the 
concentration-dependent  mediator release in MC triggered 
with anti-IgER Ab. Preincubation with KL not only con- 
siderably enhanced histamine as well as leukotriene release 
in response to optimal concentrations of anti-IgER  Ab, but 
also rendered the MC responsive to Ab concentrations that 
were otherwise unable to induce mediator release. In the pres- 
ence of KL, "o30-fold lower concentrations of anti-IgER Ab 
were required to induce the release of comparable amounts 
of mediators. Qualitatively identical results were obtained by 
stimulating MC with polyclonal or monoclonal anti-IgE Ab 
instead of anti-IgER Ab.  However,  the release induced by 
anti-IgE Ab was clearly more variable among different MC 
preparations, and in some experiments MC mediator was de- 
tectable only in the presence of KL (data not shown). 
KL Dose Restmnsa  Fig.  3 shows the dose-dependent poten- 
tiation  of IgE-dependent  histamine  and LTC4 release after 
preincubation of human lung MC with variable concentra- 
tions of human KL and murine KL. KL affected MC medi- 
ator release at concentrations considerably (10-100-fold) lower 
than previously established for synergistic bone marrow pro- 
genitor cell proliferation (18-20). The enhancement of medi- 
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Figure  2.  KL  effect  on  the 
dose-dependent  mediator  release 
by MC in response to IgE-receptor 
stimulation.  MC were exposed to 
buffer or increasing concentrations 
of anti-IgER  Ab without (open 
symbols) or with (filled symbols) 
preincubating  the cells  with  10 
ng/ml human KL. Otherwise ex- 
perimental conditions were as in 
Fig.  1. Mean  +  SEM from four 
independent  experiments  with 
different  MC  preparations  per- 
formed in duplicates  are shown. 
ator release was dose dependent from 100 pg to 1 ng/ml of 
rhuKL and became maximal at 3.3 ng/ml (Fig. 3). It is of 
interest that murine KL was nearly as active as the human 
protein on human lung MC. Similar results were obtained 
with unpurified COS supernatants transfected with soluble 
murine KL, giving half-maximal activity at a 1:200 dilution 
in the MO-7 proliferation assay (22).  For MC mediator re- 
lease, the EDs0 ranged from  1:30,000  to  1:3,000,  and the 
ED100 from  1:3,000  to  1:1,000 (three  experiments,  not 
shown),  again indicating  that  even  in  the  heterologous 
mouse-human MC assay, mediator release is enhanced at con- 
siderably lower concentrations of KL than required for cell 
proliferation. 
Kinetics of  MC Mediator Releas~  Human lung MC released 
histamine within 1-3 min of exposure to anti-IgER Ab. The 
onset  of release of the  newly  synthesized  LTC4 occurred 
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Figure  3.  KL  dose  response. 
MC were exposed to buffer or to 
0.01-100 ng/mi of either human 
(circles) or murine (triangles) KL for 
20 min and then triggered  with 
100  ng/ml  anti-IgER  Ab.  No 
mediator release was observed in 
cells e=cposed to KL alone. Means 
+  SEM of four separate experi- 
ments with different MC prepa- 
rations performed  in duplicates  are 
shown. 60 
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Figure 4.  Kinetics of MC me- 
diator release reaction. MC with 
(filled triangles)  or without (open 
triangles)  pretreatment by human 
KL (10 ng/ml, 20 min) were ex- 
posed to anti-IgER Ab (100 ng/ 
ml) at time 0. The time-dependent 
mediator release  is  shown.  The 
open circles indicate mediator re- 
lease in the absence of anti-IgER 
Ab, which did not differ with and 
without KL preincubation. Each 
symbol depicts the mean of dupli- 
cate determinations in one repre- 
sentative  experiment out of three. 
somewhat later,  and 10 min were required for maximal re- 
lease  (Fig.  4).  The  spontaneous  mediator  release  remained 
close to zero over 0-40  min of incubation.  In the presence 
of human KL,  the release of both preformed and newly syn- 
thesized mediators was strongly enhanced, but the time course 
of the release  reaction was  not  altered. 
Variation of  the Time Interval between  Addition of  KL and Anti- 
IgER Antibody.  Fig. 5 shows that the amount of mediators 
released by lung MC  varied depending on the time interval 
of addition of KL and anti-IgER..  The optimal intervals be- 
tween the addition of the stimuli were different for the en- 
hancement  of histamine  and  leukotriene  release.  Maximal 
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Figure 5.  Effect of varying the time interval between addition of KL 
and anti-IgEK Ab on MC mediator release. MC were exposed to human 
KL (10 ng/ml) and anti-IgEg. Ab (100 ng/ml). Time 0 indicates simul- 
taneous addition of the ligands,  positive time values indicate the time in- 
terval between KL and anti-IgER Ab addition, negative time values rep- 
resent the interval between the addition of the stimuli in a reversed sequence. 
The total incubation time was 80 rain; this time was identical for all con- 
ditions and sufficient for a complete release reaction. The horizontal dotted 
line indicates mediator release in response to stimulation with anti-lgER 
Ab alone. Each data point represents a single determination from one ex- 
periment out of three. 
Table  1.  Mast Cell/Basophil Mediator-releasing  Substances 
Human lung  Human 
mast cells  basophils 
Agonist  Trigger Modulator Trigger Modulator Reference 
Anti-IgE  +  +  -  +  +  -  12,13,15 
Anti-IgER  +  +  +  -  +  +  +  -  * 
FMLP  -  ND  +  +  ND  13,15 
C5a  -  ND  +  +  ND  14 
C3a  -  ND  + *  ND  25 
PAF  -  -  + *  -  23 
SP  -  -  ( + )*  -  * 
rhulL-1  -  -  -  +  15,35,43 
rhu  IL-2  ....  * 
rhu  IL-3  -  -  -  +  +  +  12-15 
rhu IL-4  ....  * 
rhu  IL-5  -  (+)  -  +  +  +  15 
rhu  IL-6  ....  * 
rhu  IL-7  ....  * 
rhu  IL-8  -  -  + *  -  24 
rhu  IL-9  ....  * 
rhu G-CSF  ....  * 
rhu M-CSF  ....  * 
rhu GM-CSF  -  -  -  +  +  +  12,13,15 
rhu TNF-a  ....  23 
rhu TGF-B  ....  * 
rhu  IFN--/  ....  * 
rhu  NGF  -  -  _  +  +  s 
rhu  FGF  ....  * 
rhu  IGF  I  -  -  -  +  * 
rhu LIF  ....  * 
KL  -  +++  -  - 
A  +  as "trigger" means a direct effect on histamine or LTCA release within 
40 min of incubation; a  +  as modulator indicates enhancement of medi- 
ator release in response to appropriate stimuli within 20 min of preincu- 
bation; a  -  indicates no effects. 
* Our unpublished results. 
s Bischoff,  S. C. and C. A. Dahinden, manuscript submitted for publi- 
cation. 
* Mediator release only after preincubation with a basophil modulator. 
Concentrations: anti-IgE and and-IgER Ab (100 ng/ml), FMLP (2.5  x 
10 -6 M), C3a (10 -6 M), C5a (10 -s M), PAF (10 -6 M), SP (2  x  10 -s 
M),  cytokines (1-100 ng/ml). 
potentiation of MC  degranulation occurred  when  KL  and 
anti-IgER Ab were added simultaneously to the MC. In con- 
trast,  a  KL  preincubation period of -10  min was  required 
for an optimal increase of LTC4 release. Curiously,  at an op- 
timal priming time for LTC4 release, we repeatedly observed 
a  concomitant,  reversible reduction  of the KL, induced  en- 
240  c-kit Ligand Potentiates Mast Cell Mediator Release hancement of histamine release. A slight enhancement of medi- 
ator release over that observed by anti-IgER Ab stimulation 
alone could even be found when KL was added shortly after 
IgE receptor stimulation (Fig.  5, negative time values). A 
constant preincubation time of 20 min was selected for the 
experiments shown in the previous sections, because of the 
discrepancy in optimal priming times for the enhancement 
of histamine and LTC4 release. 
Comparison of  Mediator Substances  for Human Lung MC and 
Basophiis.  Several  cytokines such as Ibl, ID3, II,9, GM-CSF, 
and NGF have been suggested as MC growth factors and/or 
secretagngnes in the rodent system (4, 16, 26). Some of these 
(IL-1, IL-3, GM-CSF,  NGF)  have been found to enhance 
basophil responsiveness (13-15;  Bischoff, S. C., and C. A. 
Dahinden, manuscript submitted for publication), while little 
is known about their effects on human lung MC. Therefore, 
many cytokines and basophil agonists were examined for their 
ability to modulate or trigger mediator release by human lung 
MC under the incubation conditions used in this study. Ex- 
periments were performed at least three times, and anti-IgER 
Ab stimulation with and without KL preincubation served 
as positive controls for the induction of mediator release and 
modulatory effects, respectively. Of the stimuli shown previ- 
ously to induce mediator release in basophils,  only IgE- 
dependent activation resulted in mediator release by human 
lung MC. Since certain basophil agonists (i.e., C3a, PAF, IL-8) 
efficiently induce basophil mediator release only in the pres- 
ence of II,3, IL-5, GM-CSF, or NGF (23-25), we examined 
whether KL renders human lung MC responsive to the IgE- 
independent agonists listed in Table 1. However, the results 
were negative. The only cytokine found to reproducibly modu- 
late IgE-dependent mediator release in MC was KL, with 
the possible exception of a minimal enhancement of medi- 
ator release by Ib5, and none of the examined cytokines trig- 
gered MC mediator release by itsdf. Finally, NGF, a potent 
activator of rodent MC and modulator of human basophils 
(16; Bischoff, S. C., and C. A. Dahinden, manuscript sub- 
mitted for publication) failed to modulate or induce medi- 
ator release of human lung MC, even after KL preincuba- 
tion,  up  to  concentrations  exceeding  by  lO0-fold  that 
maximally effective in human basophils (data not shown). 
Discussion 
The multiple functions of KL, a gene product of the Steel 
locus in the mouse, are emphasized by the facts that the KL- 
encoding gene is highly conserved in mammals and that Steel 
mutations lead to various symptoms such as anemia, deficien- 
des in MC and leukocyte progenitor cells, alterations of the 
coat  color,  and  defective  gonadal development (17, 18). 
Whereas potent stimulatory activities of KL on human bone 
marrow progenitor cell proliferation, particularly in syner- 
gism with other growth factors, are well established (18-20), 
further biological activities in the human system are not yet 
known. The present study shows that KL may have an im- 
portant proinflammatory effect by strongly enhancing the re- 
lease of preformed and de novo synthesized inflammatory 
mediators in  mature human lung MC  triggered by  IgE 
receptor stimulation. 
MC priming by human KL occurs at surprisingly low con- 
centrations (0.1-3 ng/ml), a fact emphasizing the possible 
in vivo importance of KL in regulating mature MC func- 
tion. The low concentrations and the short time required 
for KL priming indicate that the effect of KL is specific and 
is mediated through the KL receptor c-hR proto-oncogene 
(27). Indeed, our findings are consistent with the presence 
of a call surface marker shared by human early myeloid pro- 
genitors and MC, as defined by a mAb recently shown to 
react with the human c-kit proto-oncogene (28, 29). Whereas 
solnhle rat KL has activity similar to that of human KL in 
human bone marrow culture assays, "~l,000-times greater 
concentrations of human KL are necessary to induce prolifer- 
ation in the murine MC/9 cell line (18). Our results further 
demonstrate a high cross-species activity of rodent KL on 
human ceils, since dose-response studies revealed a similar 
potency of human and murine KL on human lung MC, al- 
beit at concentrations one to two orders of magnitude below 
that reported to induce ceU proliferation (18-20). 
The kinetics of the release reaction in human lung MC 
are similar to those previously observed in human basophils 
and lung-derived MC in response to IgE receptor-dependent 
activation (13, 30,  31). Preincubation of human MC with 
KL did not accderate the kinetics of mediator release upon 
IgE receptor stimulation, in contrast to Ib3 preincubadon 
in human basophils (13). For this study we preferred to use 
anti-IgEK Ab instead of the anti-IgE Ab used by other groups 
for activation of MC through the IgE receptor, since the ex- 
tent of mediator release in response to anti-IgER Ab was 
often higher, and the variability  of the response was less in 
comparison to anti-IgE Ab, possibility because of indepen- 
dence  of receptor  crosslinking from  surface-bound  IgE. 
Moreover,  ceil activation by a mAb directed against the c~ 
chain of the IgE receptor is probably the most specific way 
to activate MC,  since these cells are the only ceil types in 
the lung known to express high-affnity IgE receptors. 
The difference in optimal KL priming times for enhance- 
ment of histamine and LTC4 release may reflect different in- 
tracellular signaling pathways for degranulation and lipid medi- 
ator synthesis in human MC. Indeed, in previous studies with 
human basophils,  we found that histamine release and leu- 
kotriene production are separately regulated (14, 15). For ex- 
ample, C5a is a potent degranulating agent in basophils but 
is unable to induce lipid mediator synthesis, unless the cells 
have not been preincubated with IF3 (14). The influence of 
the time interval between addition of a modulatory cytokine 
(KL or IL-3) and a triggering agent upon mediator release 
by MC and basophils, respectivdy, is remarkably similar. How- 
ever, when basophils are activated by a G protein-cuupled 
receptor, such as the C5a receptor, a short preincubation period 
with the cytokine is required for agonist-induced LTC4 for- 
mation (14, 15). Neverthdess, when basophils  are exposed 
to IL-3 and anti-IgER Ab at different time intervals,  an al- 
most identical pattern of mediator release is obtained (our 
unpublished data),  as shown here for MC. 
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sponses has been described in several inflammatory effector 
cell types, including human neutrophils,  eosinophils,  and 
basophils (9-15). The effect of MC priming by KL is strik- 
ingly similar to that of I1.-3, IL-5, GM-CSF, and NGF in 
basophils (13-15; Bischoff, S. C., and C. A. Dahinden, manu- 
script  submitted for publication).  In both cases, maximal 
priming requires preincubation  with cytokine for <20 min 
before addition of the second agonist, and the effect consists 
of an enhancement of  both the release  of  preformed and newly 
synthesized mediators in response to optimal concentrations 
of the triggering agent, as well as an increase in sensitivity 
to lower concentrations of the secretagogues (13, 15). These 
analogies between human basophils and MC may suggest 
a similar mechanism of priming in both cell types. In this 
regard, it is interesting that the intracellular domain of c-kit 
has tyrosine kinase activity (27) and that very recently a high- 
affinity receptor component for NGF has been identified as 
the trk  proto-oncogene, a member of the tyrosine kinase 
receptor family (32, 33).  Furthermore, despite the lack of 
tyrosine kinase domains in receptors for GM-CSF and Ib3 
belonging to the cytokine receptor family, tyrosine phosphory- 
lation has been demonstrated in IL-3-dependent  cell lines (34). 
These observations  suggest  that tyrosine phosphorylation 
events may be critical in regulating release of mediators by 
mature human basophils and MC, a hypothesis consistent 
with our unpublished  results. 
In contrast to basophils and other inflammatory effector 
cells, little is known about cytokines capable of enhancing 
mediator release in human mucosal MC. Only IL-1 has been 
reported to augment lipid mediator synthesis in lung-derived 
human MC triggered with grass pollen antigen after prein- 
cubation of the cells with serum of sensitized individuals (35). 
The effect of II.-1 on histamine release was not examined. 
The reason for this discrepancy with our findings is unclear, 
and may be attributed to a different method of cell stimula- 
tion, or to differences in buffer conditions and incubation 
times. Another indication for cytokine-dependent  enhance- 
ment of MC mediator release came from studies of Levi- 
Schaffer et al. (36), who showed that coculture of human 
lung MC with mouse 3T3 fibroblasts for 7 d not only prolongs 
MC survival but also enhances lipid mediator release in re- 
sponse to anti-IgE Ab (36). Although a direct comparison 
of the function of MC cultured in the presence or absence 
of 3T3 fibroblasts could not be made because MC do not 
survive without fibroblasts, it is tempting to speculate that 
this functional enhancement is indeed due to KL expressed 
in 3T3 fibroblasts (37, 38). 
Several cytokines including Ib3, Ib-4, I1.-9, GM-CSF, and 
NGF have been reported to act as growth factors and/or 
secretagogues for MC in rodents (4,  16, 26), but whether 
these cytokines affect  human MC growth or function is largely 
unknown. Parallel to KL, a large number of these and other 
cytokines were examined under identical experimental con- 
ditions and were found to be ineffective in either inducing 
or modulating release of human MC mediators. Of partic- 
ular interest is the ineffectiveness of NGF, M-CSF, and II.-3 
on human lung MC function. NGF promotes release  of  medi- 
ators from peritoneal rat MC and induces a change in the 
phenotype of murine mucosal MC to connective tissue MC 
(16, 39), similar to KL in the murine system (40). M-CSF, 
a growth factor of the monocyte lineage, and its receptor 
show homologies to KL and c-kit, respectively, suggesting 
similarities in the mode of action by these two cytokines (27, 
41). Therefore,  the negative results obtained  with M-CSF 
may indicate a lack of M-CSF receptors on MC from human 
lung. Finally, Ib3, a major growth factor of mucosal MC 
in rodents, was also ineffective  on human lung MC, a finding 
consistent with a recent report demonstrating the lack oflb3 
receptors on human lung MC (42). 
Some of the cytokines acting on murine MC (II.-3, GM- 
CSF, and NGF) appear to affect human basophil function 
(13-15; Bischoff, S. C., and C. A. Dahinden, manuscript sub- 
mitted for publication) but seem ineffective in human lung 
MC. These observations indicate that data obtained from ro- 
dents are not easily transferable to the human system, and 
that murine mucosal MC have more functional resemblance 
to human basophils than to human mucosal MC. Further- 
more, human basophils and lung MC differ in their respon- 
siveness towards IgE-independent  agonists, since C3a, C5a, 
FMLP, PAF, and II.-8, all of which activate basophils (13-15, 
23-25),  are unable to induce release of mediators in human 
lung MC. It is clear, however, that the list of negative results 
presented in this study does not exclude the possibility that 
some of these bioactive molecules may affect human lung 
MC under different experimental conditions or with regard 
to other cellular responses. 
Murine KL is expressed in a biological active form as a 
membrane-bound protein and is also active in a soluble form 
(22, 38). The extent of KL expression in human adult lung 
tissue is unknown. The fact that KL promotes a phenotyp- 
ical alteration  of mucosal MC to connective tissue MC in 
the rodent system (40) may indicate that KL is not strongly 
expressed in lung tissue, since lung MC are predominantly 
of the mucosal phenotype. Nevertheless, it cannot be excluded 
that the Kl.-induced potentiation of mediator release in dis- 
persed lung MC demonstrated in this study is due to their 
separation from lung tissue cells expressing KL.  However, 
the fact that KL, at very low concentrations,  strongly en- 
hances MC mediator release, even in unpurified MC prepara- 
tions containing other lung tissue cells, argues against this 
possibility. In any case, our study raises the important ques- 
tion of  whether expression  of KL can be upregulated in human 
lung diseases such as asthma and other MC-associated pa- 
thologies. 
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